In the Pipeline
• Guilford Pharmaceuticals has initiated a Phase III clinical development program for Aquavan injection, a novel sedative/hypnotic that is a proprietary water-soluble prodrug of propofol.
• Vicuron Pharmaceuticals has completed enrollment in three Phase III clinical trials involving more than 1,500 patients designed to support registration of once-weekly dalbavancin for the treatment of skin and soft-tissue infections.
• Coley Pharmaceutical Group has completed the planned enrollment for its Phase II, randomized clinical study of the company’s lead TLR Therapeutic, CPG 7909 (ProMune), for the treatment of non-small cell lung cancer.
• InterMune has initiated a Phase II clinical trial of the combination of interferon alfacon-1 (Infergen) and interferon gamma-1b (Actimmune) for the treatment of patients chronically infected with hepatitis C virus who have failed to respond to therapy with pegylated interferon alpha-2 plus ribavirin.
• Millennium Pharmaceuticals has initiated a multicenter Phase II clinical trial of bortezomib (Velcade) for Injection in combination with rituximab in patients with relapsed or refractory indolent (follicular and marginal zone) non-Hodgkin’s lymphoma.
Guilford Pharmaceuticals has initiated a Phase III clinical development program for Aquavan injection, a novel sedative/hypnotic that is a proprietary water-soluble prodrug of propofol.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.